Provides details on how insurers’ treatment of manufacturer copay assistance affects patients’ out-of-pocket spending and how high costs drive up prescription abandonment rates, especially while patients deal with the economic effects of COVID.
![Ensuring patients can afford their medications during COVID-19](https://hivhep.org/wp-content/uploads/2020/08/Screen-Shot-2021-02-18-at-9.57.11-AM-1080x675.png)
Ensuring patients can afford their medications during COVID-19
read more